(EKOP) Ekopak BV - Ratings and Ratios

Ekopa NV specializes in designing, building, financing, and operating industrial water processing solutions across Belgium, France, and international markets. The company operates through two primary segments: Water-as-a-Service (WaaS) and Non-WaaS. Its offerings include cooling and feed water treatment, boiler and feed water treatment, process water treatment, corrosion control, ultra-filtration, legionella prevention, and disinfection. Ekopa NV also provides chemicals for internal water treatment to protect against corrosion and deposits in steam boilers, hot water and heating circuits, drinking water systems, and cooling towers.

The company designs, constructs, and optimizes a wide range of water treatment equipment, including dosing stations, disinfection units, water softeners, decarbonation and demineralization units, reverse osmosis systems, filtration units, and physico-chemical and biological wastewater stations. These solutions cater to industries such as pharmaceuticals, cosmetics, chemicals, food and beverage, and pulp and paper. Ekopa NV was founded in 1997 and is headquartered in Tielt, Belgium. For more information, visit https://ekopak.be.

Ticker Symbol: EKOP is listed on the BR exchange as a common stock. The company operates in the Water Utilities sector under the GICS Sub Industry classification.

Three-Month Forecast: Based on the provided and , Ekopa NVs stock (EKOP) is expected to face downward pressure in the near term. The SMA 20 (13.82) and SMA 50 (14.15) are both below the SMA 200 (16.29), indicating a potential bearish trend. The average trading volume of 6,587 shares suggests limited liquidity, which could amplify price volatility. The ATR of 0.40 indicates moderate price movement. On the fundamental side, the negative ROE (-13.68) raises concerns about profitability, which could weigh on investor sentiment. The forward P/E and P/E ratios are zero, signaling uncertainty or lack of analyst consensus. Overall, the stock is likely to remain under pressure over the next three months, with limited upside potential.